Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
- Conditions
- RetinoblastomaRetinoblastoma, Recurrent
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Eye & ENT Hospital of Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT06972602
- Locations
- 🇨🇳
Fudan Eye & ENT Hospital, Shanghai, China
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
- Target Recruit Count
- 450
- Registration Number
- NCT06954246
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Nerviano Medical Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT06930755
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 468
- Registration Number
- NCT06855069
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Study of SHR-A1811 in Subjects With Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06828354
- Locations
- 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment
- Conditions
- Retinal Detachment RhegmatogenousProliferative Vitreoretinopathy
- Interventions
- Procedure: Retinal detachment surgery
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 394
- Registration Number
- NCT06818721
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- First Posted Date
- 2025-01-30
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 695
- Registration Number
- NCT06801834
- Locations
- 🇦🇺
Cancer Care Wollongong, New South Wales, Australia
🇺🇸The University of Texas Health Science Center at Tyler, Tyler, Texas, United States
🇺🇸Hope and Healing Cancer Services, Hinsdale, Illinois, United States
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
- Conditions
- Ovarian CancerPrimary PeritonealFallopian Tube Cancers
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 430
- Registration Number
- NCT06751485
Chronic CED of TPT for Recurrent Malignant Glioma
- Conditions
- Brain Tumor, RecurrentMalignant Glioma (WHO Grade III or IV)IDH1/IDH2 Mutation
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Jeffrey N. Bruce
- Target Recruit Count
- 6
- Registration Number
- NCT06666712
- Locations
- 🇺🇸
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
- Conditions
- Pleuropulmonary Blastoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Bone ScanOther: Patient ObservationProcedure: Ultrasound ImagingProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission Tomography
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 110
- Registration Number
- NCT06647953
- Locations
- 🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.